Associated Papers
Evaluation of urinary cfDNA workflows for the molecular profiling of malignant disease.
Eberhard A et al.
Iscience, 2025
41142998 (PubMed )
Supplement: mmc3.xlsx › Supplementary_Table_2
Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma.
Zwimpfer TA et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
41040691 (PubMed )
Supplement: media-2.xlsx › Supplementary_Table_S12
Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma.
Ansari-Pour N et al.
Blood, 2023
36223594 (PubMed )
Supplement: BLOOD_BLD-2022-017010-mmc2.xlsx › Supplementary_Table_S2
Mosaicism in Tumor Suppressor Gene Syndromes: Prevalence, Diagnostic Strategies, and Transmission Risk.
Chen JL et al.
Annual Review of Genomics and Human Genetics, 2022
36044908 (PubMed )
Supplement: gg23-giannikou_suptable1.xlsx › RB1
Chemotherapy modulates CDK4/6 inhibitors resistance in metastatic breast cancer by Rb1 mutations: a case report and literature review.
Gao L et al.
Annals of Translational Medicine, 2022
Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer.
Vandekerkhove G et al.
Nature Communications, 2021
33420073 (PubMed )
Supplement: 41467_2020_20493_MOESM3_ESM.xlsx › Supplementary_Data_4
Mutational analysis of the RB1 gene and the inheritance patterns of retinoblastoma in Jordan.
Yousef YA et al.
Familial Cancer, 2018
Defective splicing of the RB1 transcript is the dominant cause of retinoblastomas.
Cygan KJ et al.
Human Genetics, 2017
Exomic sequencing of four rare central nervous system tumor types.
Bettegowda C et al.
Oncotarget, 2013
23592488 (PubMed )
Supplement: oncotarget-04-572-s001.xlsx › supp_table_1a
Select a paper to view details